Hyaluronic acid-based gels including lidocaine
AssigneeAllergan Industrie, SAS
InventorPierre F. Lebreton
Life of this patent
Estimating the term…
Abstract
Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. Some of the hyaluronic acid-based compositions can include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. Compared to conventional compositions that include lidocaine, some of the hyaluronic acid-based compositions disclosed herein can have an enhanced stability, for example, when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such compositions are also provided.
Claims26
A soft tissue filler composition comprising a mixture of soluble form hyaluronic acid (HA), particles of HA crosslinked with 1,4-butanediol diglycidyl ether (BDDE), and lidocaine in an amount effective to mitigate pain upon injection of the mixture.
A soft tissue filler comprising a hyaluronic acid (HA) component comprising HA crosslinked with 1,4-butanediol diglycidyl ether (BDDE) and uncrosslinked HA, wherein the crosslinked HA has a degree of crosslinking of about 2% to about 20%.
A dermal filler comprising particles of crosslinked HA in a fluidic medium of uncrosslinked HA, wherein the crosslinked HA is crosslinked with 1,4 butanediol diglycidyl ether (BDDE), and wherein the particles of crosslinked HA have a degree of crosslinking of less than about 6%;
- and lidocaine in an amount effective to mitigate pain upon injection of the dermal filler.
A method of preparing a hyaluronic acid (HA) based composition comprising:
- providing a hyaluronic acid (HA)-based gel crosslinked with 1,4-butanediol diglycidyl ether (BDDE);
- pressing the crosslinked HA-based gel through a mesh to produce crosslinked HA particles;
- mixing the crosslinked HA particles with a carrier material to produce the HA-based composition;
- adding lidocaine to the HA-based composition to form a HA/lidocaine gel mixture;
- and homogenizing the HA/lidocaine gel mixture.
Dependencies are inferred from the claim text.